Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Reversine Protocol Guide for Aurora Kinase Studies
2026-08-17
Reversine (SKU A3760) provides a research reagent for probing Aurora kinase activity, mitotic control, cancer cell proliferation inhibition, and related apoptosis readouts. It is suitable for controlled in vitro experiments and exploratory cancer models, but biochemical IC50 values should not be treated as validated cellular doses or clinical evidence.
-
Cediranib (AZD2171) In Vitro Research Guide
2026-08-17
Cediranib (AZD2171) combines potent VEGFR blockade with a workflow that separates pathway suppression from actual cell killing. This guide shows how to use it in angiogenesis, signaling, viability, and tumor-model assays while avoiding common interpretation and handling errors.
-
MG-262 Workflows for Proteasome Inhibition Studies
2026-08-16
MG-262, also called Z-Leu-Leu-Leu-B(OH)2, provides reversible, cell-permeable control of proteasome chymotryptic activity for time-resolved studies of ubiquitin accumulation, apoptosis, and cell-cycle regulation. Its value is especially clear when proteasome measurements are paired with inflammatory BIRC2/BIRC3 profiling in epithelial models or differentiation assays.
-
EMD638683: SGK1 Inhibitor Workflows
2026-08-15
EMD638683 enables mechanism-focused SGK1 inhibition in endothelial stiffness, sodium-sensitivity, cancer, and cell-signaling studies. This guide connects phospho-NDRG1 assays with actin remodeling and phenotypic readouts while emphasizing selectivity controls, formulation, and troubleshooting.
-
PBA-Modified PAD4 Inhibitors Target Tumor NETs
2026-08-14
The reference study developed phenylboronic acid-modified PAD4 inhibitors to improve tumor-associated uptake while suppressing the PAD4–H3cit–NET pathway. Its findings connect tumor-selective delivery with reduced breast cancer growth, metastasis, and immune-microenvironment changes in preclinical models.
-
Carbapenemase Transmission in CREC Across Guangdong
2026-08-14
Chen et al. characterized carbapenemase-encoding genes, their plasmid or chromosomal locations, transferability, mobile genetic elements, and clonal relationships in 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals. The predominance and high conjugative transfer rate of plasmid-associated blaNDM-1 highlight the importance of combining molecular surveillance, susceptibility testing, and infection-control investigations in antibiotic resistance research.
-
AAPH: From Radical Chemistry to Translational Models
2026-08-13
A mechanistic and strategic guide to using AAPH (2,2'-Azobis(2-methylpropionamidine) dihydrochloride) for reproducible oxidative stress modeling, antioxidant evaluation, membrane injury studies, and cross-domain translational research.
-
Recombinant Annexin V: A Faster Purification Workflow
2026-08-13
Burger and colleagues reported a short purification strategy for recombinant annexin V that combines mild bacterial-cell opening, reversible calcium-dependent liposome binding, and final ion-exchange chromatography. The approach produced protein suitable for crystallography, electron microscopy, spectroscopy, and single-channel measurements while addressing contamination introduced by harsher cell-disruption methods.
-
Eldecalcitol, Endothelial Ferroptosis, and T2DOP
2026-08-12
A 2025 study links endothelial ferroptosis to impaired osteogenesis–angiogenesis coupling in type 2 diabetic osteoporosis and identifies the SOCE/O-GlcNAcylation axis as a mechanism regulated by eldecalcitol. Its integrated cell and mouse experiments suggest that protecting endothelial function may help preserve bone formation under diabetic metabolic stress.
-
Ceftazidime: A Phenotype-to-Genotype Bridge
2026-08-12
Ceftazidime is a third-generation cephalosporin that connects susceptibility phenotypes with resistance-gene and plasmid-transmission research. This article explains how to use its activity against Gram-negative organisms, especially Pseudomonas aeruginosa, without overinterpreting clinical isolate data.
-
γH2AX DNA Damage Detection Kit: From Signal to Decision
2026-08-11
The γH2AX DNA Damage Detection Kit provides a spatial readout of DNA double-strand break signaling. This guide explains how to interpret γ-H2AX foci in radiosensitizer, apoptosis, genotoxicity, and DNA repair studies using evidence from recent FLASH-RT research.
-
Azilsartan Medoxomil Monopotassium in AT1 Studies
2026-08-11
Azilsartan medoxomil monopotassium (TAK 491) provides a sustained, selective AT1-receptor blockade framework for hypertension and cardiovascular research. This article connects receptor pharmacology with the ARAMIS angiotensin II conversion study to improve assay design and translational interpretation.
-
Nigericin Sodium Salt: Practical Protocol Guide
2026-08-10
Nigericin sodium salt is a potassium ionophore for controlled studies of K+/H+ exchange, ion transport across biological membranes, and cytoplasmic pH changes. This guide covers practical preparation and assay controls, while defining limits for platelet, lead-transport, and cell-based applications when no directly matched paper evidence is available.
-
Carbenoxolone disodium: Practical QC Guide
2026-08-09
Carbenoxolone disodium is an 11β-hydroxysteroid dehydrogenase inhibitor for controlled cell- and tissue-based studies of glucocorticoid access, corticosterone metabolism, and gap junction communication. This guide covers preparation, quality control, and interpretation limits; it should not be treated as an in vivo efficacy protocol or a selective off-target-free intervention.
-
Guanabenz Acetate in Stress-Response Assays
2026-08-08
Guanabenz Acetate provides a receptor-centered way to perturb α2-adrenergic signaling while monitoring stress-granule and innate-immune phenotypes. This practical workflow connects subtype-aware pharmacology with the GADD34–IRF3 mechanism described in SARS-CoV-2 nucleocapsid research, without treating the compound as a validated antiviral rescue agent.